Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC).

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study
designed to evaluate the efficacy and safety of alisertib, an Aurora A kinase inhibitor, in
combination with paclitaxel compared with placebo + paclitaxel in patients with SCLC who
have relapsed or did not respond to first line standard therapy.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Randomization will be stratified by the type of relapse after primary treatment (sensitive
or resistant/refractory disease) and presence of brain metastases.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00007849
  •   2015/05/18
  •   2013/12/04
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1154-9805 
  •   2013-003713-18 
  •   NCT02038647  (
  •   C14018  (Millennium Pharmaceuticals, Inc.)
  •   2013-003713-18 
  •   U1111-1154-9805 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Small Cell Lung Cancer (SCLC)
  •   C34 -  Malignant neoplasm of bronchus and lung
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Alisertib (MLN8237)
  •   Drug: Placebo
  •   Drug: Paclitaxel 60 mg/m2
  •   Drug: Paclitaxel 80 mg/m2
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Single arm study
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist, assessor
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Progression-free survival (PFS); time frame: Up to 22 months

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Overall survival (OS); time frame: Up to 22 months
- Overall response rate (ORR), including complete response rate (CRR); time frame: Duration of study until disease progression up to 22 months.
- Safety and health related quality of life (HRQOL); time frame: From screening period to the specified number of PFS events up to 22 months.
- Biomarker correlative studies including circulating tumor cells and circulating DNA assessments; time frame: Twice in cycle 1 in a 28-day cycle
- Disease control rate (DCR); time frame: From screening period to 30 days after last dose of study drug up to 22 months.
- Duration of response (DOR); time frame: From screening period to 30 days after last dose of study drug up to 22 months.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   United States
  •   Belgium
  •   Canada
  •   Czech Republic
  •   France
  •   Germany
  •   Hungary
  •   Italy
  •   Poland
  •   Spain
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2014/02/27
  •   166
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Inclusion Criteria

Each patient must meet all the following inclusion criteria to be enrolled in the study:

1. Male or female patients ≥ 18 years old

2. Have a pathologically (histology or cytology) confirmed diagnosis of SCLC

3. Have received and progressed after a platinum-based standard chemotherapy regimen for
first line treatment of SCLC, either limited stage (LS) or extensive stage (ES).

4. Have measurable disease within ≤ 2 weeks before randomization. Clear radiographic
evidence of disease progression after initial therapy should have been documented.

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (PS 0-1).

6. Patients with treated brain metastases (surgery, whole or stereotactic brain
radiation) are allowed provided the lesions have been stable for at least 2 weeks and
the patient is off steroids or is on a stable dose of steroids. Patients should be
without neurologic dysfunction that would confound the evaluation of neurological
and/or other AEs.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Exclusion Criteria

Patients meeting any of the following exclusion criteria are not to be randomized to

1. Any prior therapy for second-line treatment of SCLC.

2. Patients who relapsed ≥ 180 days after their response to first-line treatment.

3. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent,
including alisertib, or any other investigational agent.

4. Prior treatment with paclitaxel or any other taxane agent.

5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.

6. Any comorbid condition or unresolved toxicity that would preclude administration of
alisertib or weekly paclitaxel.

7. Prior history of ≥ Grade 2 neurotoxicity that is not resolved to ≤ Grade 1

8. Patients with symptomatic and/or progressive brain metastases or with carcinomatous

9. Treatment with clinically significant enzyme inducers within 14 days prior to the
first dose of alisertib and during study conduct. Major prohibited enzyme inducers
include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine,
and St. John's wort.

10. Inability to swallow alisertib or other orally administered medications.

11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist, or
pancreatic enzymes.

12. Diagnosed with or treated for another malignancy within 2 years before the first dose
of study drug, or previously diagnosed with another malignancy and have any evidence
of residual disease.

13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.

14. History of myocardial infarction, unstable symptomatic ischemic heart disease,
uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac
arrhythmias of Grade > 2, thromboembolic events (eg, deep vein thrombosis, pulmonary
embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg,
pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving
the first dose of study drug.

15. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or
hepatitis C.

16. Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and
not fully recovered to baseline or to a stable clinical status.

17. Patients who are pregnant, lactating, or do not agree to use effective methods of
contraception during the study treatment period through 6 months after the last dose
of study drug per protocol.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Millennium Pharmaceuticals, Inc.
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Millennium Pharmaceuticals, Inc.
    • Medical Monitor 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   4
  •   2015/02/24
* This entry means the parameter is not applicable or has not been set.